Piper Sandler Cuts Natera (NASDAQ:NTRA) Price Target to $70.00

Natera (NASDAQ:NTRA – Get Rating) had its price target cut by Piper Sandler from $80.00 to $70.00 in a research note published on Monday morning, MarketBeat reports. They currently have an overweight rating on the medical research company’s stock. Piper Sandler also issued estimates for Natera’s Q1 2022 earnings at ($1.39) EPS, Q2 2022 earnings […]

Related Keywords

,Roelof Botha ,Steven Leonard Chapman ,Piper Sandler ,Robertw Baird ,Morgan Stanley ,Natera Inc ,Selective Wealth Management Inc ,Evolution Wealth Advisors ,Zacks Investment Research ,Goldman Sachs Group ,Natera Company Profile Get Rating ,Get Rating ,Investment Research ,Director Roelof Botha ,Leonard Chapman ,Wealth Advisors ,Wealth Management ,Company Profile ,Natera ,Nasdaq Ntra ,Ontra ,Medical ,Lower Price Target ,